Lannett Company (NYSE:LCI) inks an agreement with Respirent Pharmaceuticals Co., Ltd. for exclusive U.S. distribution rights to the latter’s generic version of GlaxoSmithKline’s (NYSE:GSK) asthma med Flovent Diskus (Fluticasone Propionate Powder Inhaler).
Per IQVIA, the U.S. market is $94M.
LCI also has exclusive U.S. distribution rights to Repirent’s generic version of GSK’s Advair Diskus (Fluticasone Propionate – Salmeterol Xinafoate Powder Inhaler), the term of which has been extended to 12 years from 10.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.